Affiliation: Medarex Inc
- Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodiesAlan Korman
Medarex Inc, 521 Cottonwood Drive, Milpitas, CA 95035, USA
Curr Opin Investig Drugs 6:582-91. 2005..These events usually respond readily to short-term anti-inflammatory treatment and cessation of drug treatment, and even when suppressed in this manner appear to correlate with clinically significant and durable antitumor responses...
- Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaquesTibor Keler
Department of Preclinical Development, Medarex, Bloomsbury, NJ 08804, USA
J Immunol 171:6251-9. 2003..Repeated dosing of the 10D1 did not elicit monkey anti-human Ab responses in the monkeys. These observations support the development of CTLA-4 blockade for human immunotherapy...
- Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patientsF Stephen Hodi
Department of Adult Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 100:4712-7. 2003..These findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients...
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsF Stephen Hodi
Department of Medical Oncology and Cancer Vaccine Center, Dana Farber Cancer Institute, Brigham and Women s Hospital and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 105:3005-10. 2008....